There is no way to judge the life expectancy of patients through the symptoms of back pain in advanced lung cancer, it needs to be analyzed in combination with treatment efficacy and physical condition. The survival time of most patients with advanced lung cancer is between 3-6 months. If the patient is insensitive to radiotherapy and has poor therapeutic efficacy, as well as the patient’s poor physical condition, the 5-year survival period is extremely low. If the lung cancer patients have EGFR gene mutation, the survival time can be prolonged through the treatment of gefitinib, erlotinib and other generation of targeted drugs; for the patients with ALK gene mutation, applying the treatment of crizotinib, the survival time for some of the patients can be more than 5 years, and if the patients give up the treatment, they will only have the survival time of about 3 months, and some of the patients will even be even shorter.